We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+3.22%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$179M
AUM Growth
-$30.2M
Cap. Flow
-$14.6M
Cap. Flow %
-8.15%
Top 10 Hldgs %
63.13%
Holding
65
New
9
Increased
21
Reduced
4
Closed
24

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$7.06M
2
VCYT icon
Veracyte
VCYT
+$6.04M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$4.72M
4
IMMU
Immunomedics Inc
IMMU
+$3.51M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.2M

Top Sells

Rank Stock Value
1
OLED icon
Universal Display
OLED
+$10.6M
2
INCY icon
Incyte
INCY
+$4.78M
3
EXEL icon
Exelixis
EXEL
+$3.75M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.17M
5
TVTX icon
Travere Therapeutics
TVTX
+$2.58M

Sector Composition

Rank Sector Weight
1 Healthcare 68.86%
2 Technology 2.12%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
26
DELISTED
ESSA Pharma
EPIX
$1.52M 0.85%
23,367
+7,242
+45% +$472K
PACB icon
27
Pacific Biosciences
PACB
$441M
$1.41M 0.79%
+165,368
New +$1.63M
EXEL icon
28
Exelixis
EXEL
$13.8B
$1.28M 0.72%
320,897
-886,829
-73% -$3.75M
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.01M 0.57%
+232,800
New +$1.04M
TLGT
30
DELISTED
Teligent, Inc
TLGT
$507K 0.28%
+10,341
New +$645K
CRDC
31
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$431K 0.24%
120,958
+2,455
+2% +$7.14K
MNKD icon
32
PUT
MannKind Corp
MNKD
$1.17B
$242K 0.14%
+30,000
New +$171K
VANI icon
33
PUT
Vivani Medical
VANI
$115M
$242K 0.14%
+2,083
New +$240K
AKTX
34
Akari Therapeutics
AKTX
$12.9M
$236K 0.13%
23
+2
+10% +$20.7K
CBMX
35
DELISTED
CombiMatrix Corporation
CBMX
$171K 0.1%
47,431
– –
NVIV
36
PUT
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$140K 0.08%
+1
New +$107K
ATRA icon
37
Atara Biotherapeutics
ATRA
$77M
– –
-3,800
Closed -$2.51M
BBW icon
38
Build-A-Bear
BBW
$424M
– –
-167,109
Closed -$2.04M
FUN icon
39
Cedar Fair
FUN
$1.8B
– –
-21,529
Closed -$1.2M
INCY icon
40
Incyte
INCY
$24B
– –
-44,078
Closed -$4.78M
NBIX icon
41
Neurocrine Biosciences
NBIX
$16.9B
– –
-56,000
Closed -$3.17M
OFIX icon
42
Orthofix Medical
OFIX
$496M
– –
-24,813
Closed -$973K
OLED icon
43
CALL
Universal Display
OLED
$3.67B
– –
-113,200
Closed -$6.16M
QQQ icon
44
PUT
Invesco QQQ Trust
QQQ
$469B
– –
-50,000
Closed -$5.59M
SAGE
45
DELISTED
Sage Therapeutics
SAGE
– –
-16,877
Closed -$984K
DCOY
46
Decoy Therapeutics
DCOY
$2.31M
– –
0
– -$1.1M
SRPT icon
47
CALL
Sarepta Therapeutics
SRPT
$1.68B
– –
-75,000
Closed -$2.89M
THC icon
48
Tenet Healthcare
THC
$20.1B
– –
-28,400
Closed -$861K
VNDA icon
49
Vanda Pharmaceuticals
VNDA
$315M
– –
-27,952
Closed -$260K
XBI icon
50
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
– –
-80,000
Closed -$5.62M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2016 Portfolio in Review

As of Q1 2016, Acuta Capital Partners held 65 positions worth $179M, down 14% from $209M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Acuta Capital Partners withdrew a net $14.6M in Q1 2016, closing 24 positions and reducing 4 holdings. Its most notable exit was Incyte, an estimated $4.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 66% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Acuta Capital Partners opened a new position in Akebia Therapeutics worth $3.48M.

  • Acuta Capital Partners's largest Q1 2016 buy was Akebia Therapeutics: 386,308 shares worth $3.48M.
  • Acuta Capital Partners added most to Amicus Therapeutics in Q1 2016, an estimated $7.06M increase.
  • Acuta Capital Partners's biggest Q1 2016 reduction was Universal Display, cutting an estimated $10.6M.
  • Acuta Capital Partners fully exited Incyte in Q1 2016, selling an estimated $4.78M.
  • Acuta Capital Partners's ten largest holdings make up 63% of its $179M portfolio in Q1 2016.
  • Acuta Capital Partners opened 9 new positions and closed 24 in Q1 2016.
  • Acuta Capital Partners's portfolio value fell 14% quarter-over-quarter to $179M.

Based on Acuta Capital Partners's 13F filing for Q1 2016, filed 13 May 2016.